Vitura Health Secures $5.1 Million Capital Injection from Professor Khalil Shahin AO

Highlights:

• $5.1 Million Capital Raise – Vitura Health Limited (ASX: VIT) secured $5.1 million from AFO Investments, linked to high-net-worth investor Professor Khalil (Charlie) Shahin AO.
• Funding for Expansion & Acquisition – The capital will support Candor Medical’s $4 million acquisition and further expansion plans, aiming to boost revenue and EBITDA in FY2025.
• Strategic Investor Onboard – Professor Shahin’s investment gives him an 11.4% stake in Vitura, reinforcing confidence in the company’s long-term growth and digital healthcare strategy.

Strategic Investment to Support Expansion and Acquisition

Vitura Health Limited (ASX: VIT), a leading digital health platform, has successfully raised $5.1 million through a share placement with AFO Investments Pty Ltd, an entity linked to high-net-worth investor Professor Khalil (Charlie) Shahin AO. This funding will primarily support Vitura's growth initiatives, including the acquisition of Candor Medical.

Key Details of the Capital Raise

At the time of writing, Vitura Health has issued 74.8 million new shares to AFO Investments at $0.06912 per share, reflecting a 10% discount to the company's five-day volume-weighted average price as of January 31, 2025. The placement, which does not require shareholder approval, brings AFO’s ownership stake to 11.4% of Vitura's total issued capital.

Utilization of Funds and Growth Prospects

The funds raised will facilitate the $4 million initial payment for Candor Medical’s acquisition, a move expected to boost Vitura’s revenue and EBITDA in FY2025 and beyond. Additionally, the capital will be directed towards the company’s broader expansion strategy.

Investor Confidence in Vitura’s Growth Potential

Vitura Chair Robert Iervasi welcomed the investment, stating that Shahin’s involvement is a strong validation of Vitura’s strategy and long-term potential. Professor Shahin echoed this sentiment, expressing enthusiasm about his stake in the company and confidence in its growth trajectory. With this funding secured, Vitura is poised to strengthen its market position and drive innovation in digital healthcare. Following the announcement, the trading halt on Vitura’s shares has been lifted.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com